Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Thiotepa - Adienne

Next Previous
Drug Profile

Thiotepa - Adienne

Alternative Names: Tepadina; Thioplex

Latest Information Update: 30 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ADIENNE
  • Developer ADIENNE; Amneal Pharmaceuticals; ESTEVE Pharmaceuticals; Gruppo Italiano Trapianto di Midollo Osseo
  • Class Antineoplastics; Aziridines; Myeloablative agonists; Organothiophosphorus compounds
  • Mechanism of Action Alkylating agents; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haematological disorders
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Adenocarcinoma; Cancer metastases; Graft-versus-host disease; Haematological disorders; Lymphoma; Papilloma; Solid tumours
  • No development reported Brain cancer

Most Recent Events

  • 12 May 2025 Kaixin Pharmaceuticals acquires Thiotepa from CASI Pharmaceuticals
  • 17 Sep 2020 No recent reports of development identified for phase-II development in Brain cancer (Combination therapy, In adolescents, In children, In infants, In neonates) in Japan (IV) (UMIN000026084)
  • 17 Sep 2020 No recent reports of development identified for phase-II development in Graft-versus-host disease (Prevention) in Italy (IV) (NCT01814488)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top